Angiopoietin-like 3

Angiopoietin-like 3

Angiopoietin-like 3 Molekülinformation

Molecule Name
Angiopoietin like 3
Molekülalias
ANGPTL3,ANGPT5,ANG-5,Angiopoietin-5,FHBL2
Drug Development Progress
Anzahl der klinischen Arzneimittel14
Anzahl der inverkehr gebrachten Arzneimittel1
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
Angiopoietin Like 3,Angiopoietin 5,UNQ153/PRO179,Angiopoietin-5,Angiopoietin-like protein 3,ANGPT5,ANG-5,Angiopoietin-Related Protein 3,Angiopoietin-Like 3,FHBL2,ANL3,ANGPTL3
Molekülhintergrund
Angiopoietin-like protein 3 (ANGPTL3) is also known as Angiopoietin-related protein 3, Angiopoietin-5 (ANGPT5 / ANG-5), is a member of the angiopoietin-like family of secreted factors. ANGPTL3 / ANGPT5 is predominantly expressed in the liver, and has the characteristic structure of angiopoietins, consisting of a signal peptide, N-terminal coiled-coil domain and the C-terminal fibrinogen (FBN)-like domain. The FBN-like domain in angiopoietin-like 3 protein was shown to bind alpha-5/beta-3 integrins, and this binding induced endothelial cell adhesion and migration. This protein may also play a role in the regulation of angiogenesis. Angptl3 also acts as dual inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL), and increases plasma triglyceride and HDL cholesterol in rodents. ANGPTL3 inhibit endothelial lipase to catalyze HDL-phospholipid and increase HDL-PL levels. Circulating PL-riched HDL particles have high cholesterol efflux abilities.

Angiopoietin-like 3 Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
ZodasiranARO-ANG3; ARO-ANG33; VSA-003 (Arrowhead Pharmaceuticals)Phase 3 ClinicalRoche Ltd
Dyslipidemias; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipoproteinemia Type II; Hypertriglyceridemia
Details
LNA-043LNA-043Phase 2 ClinicalNovartis Pharma Ag
Knee Injuries; Osteoarthritis; Osteoarthritis, Knee
Details
VupanorsenISIS-703802; PF-07285557Phase 2 ClinicalIonis Pharmaceuticals Inc
Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Homozygous familial hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
EDP-167EDP-167; EDP167Phase 2 ClinicalEteng Pharmaceutical (Zhuhai) Co Ltd
Dyslipidemias; Homozygous familial hypercholesterolemia
Details
ALN-ANG3ALN-ANG3Phase 2 ClinicalAlnylam Pharmaceuticals Inc
Diabetic Nephropathies
Details
BW-00112BW-00112; BW00112Phase 2 ClinicalShanghai Argo Biopharmaceutical Co Ltd
Dyslipidemias; Hypertriglyceridemia
Details
SolbinsiranLY-3561774; DCR-CM-1; DCR-CM1Phase 2 ClinicalDicerna Pharmaceuticals Inc
Cardiovascular Diseases; Dyslipidemias; Hyperlipoproteinemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases
Details
JS-401JS-401; RP-912Phase 1 ClinicalRisen (Suzhou) Pharma Tech Co Ltd
Hyperlipidemias; Metabolic Diseases
Details
VERVE-201VERVE-201Phase 1 ClinicalBroad Institute, Harvard University
Atherosclerosis; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia
Details
SYH-2070SYH2070; SYH-2070Phase 1 ClinicalCspc Heibei Zhongrun Pharmaceutiacl Co Ltd
Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypertriglyceridemia
Details
NN-6491NN6491; NN-6491Phase 1 ClinicalNovo Nordisk A/S
Cardiovascular Diseases
Details
NNC0491-6075NNC0491-6075; NNC04916075Phase 1 ClinicalNovo Nordisk A/S
Dyslipidemias
Details
AZD-1705AZD1705; AZD-1705Phase 1 ClinicalAstrazeneca Plc, Parexel International Corp
Cardiovascular Diseases
Details
CTX-310CTX-310; CTX310Phase 1 ClinicalCrispr Therapeutics Ag
Cardiovascular Diseases; Dyslipidemias; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases; Sitosterolemia
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
EvinacumabREGN-1500ApprovedRegeneron Pharmaceuticals IncEvkeezaUnited StatesHypercholesterolemia; Homozygous familial hypercholesterolemiaRegeneron Pharmaceuticals Inc2021-02-11
Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia; Metabolic Diseases
Details